Ann: Appendix 4C - quarterly, page-83

I take into account that most biotechs will take a decade to mature due to the regulatory burden.

Then I consider that MSB has a game changing technology and has been at the forefront of changing the regulatory burden to accelerate stem cell therapies vs slow and costly drug therapies.

Then I consider the realities of how the science is performing.

Then I consider the role of manipulators in the market and the range of antics they get up to.

Then I'm pretty resolute about people who use only the rear vision mirror to guide future decisions.
Or people who try to make you impatient about their holdings because they want you to freak out at the SP.
Or try to taunt you.... with oversimplifications.